Management of advanced Hodgkin’s lymphoma

Published: June 8, 2009
Abstract Views: 157
PDF: 441
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The relative safety of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and its demonstrated equivalence or superiority to MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) or MOPP-containing regimens, including hybrid regimens, in prospective trials led to its widespread use as the standard regimen for the treatment of Hodgkin lymphoma.The ABVD regimen is shown in Table I. In all instances, the patients treated with MOPP or its variants had the known higher rates of septic complications due to the greater degree of myelosuppression as well as an increased likelihood of developing myelodysplasia or acute leukemia compared to ABVD. The ABVD regimen did not appear to have permanent sterilization as a toxic effect.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Canellos, G. (2009). Management of advanced Hodgkin’s lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.403